IPO Premiums
IPO calendar
ZDListed

Zenith Drugs Limited

Book Built Issue IPO · NSE

Price band
₹75 - ₹79
Lot size
1,600 shares
Issue amount
₹40.68 cr
Total subscription
179.07×
Current price₹39
Listing price ₹110
Watch live price ↗
Opens
19 Feb 2024
Closes
22 Feb 2024
Allotment
23 Feb 2024
Listing
27 Feb 2024

Offer at a glance

Issue overview

Issue size
51,48,800 shares
Face value
₹10 Per Equity Share
Minimum investment
₹1,20,000
Fresh issue
₹40.68 cr
Offer for sale
₹0 cr
Registrar
Bigshare Services Private Limited
Listing exchange
NSE
Maximum investment
₹1,26,400
Issue type
Book Built Issue IPO
Shares before issue
1,20,00,000
Shares after issue
1,71,48,800

Lot sizes

CategoryLotsSharesAmount
RETAIL11,600₹1,26,400
HNI23,200₹2,52,800

Share reservation

Retail29.21%
NII(HNI)12.52%
QIB16.69%
Market Maker16.56%

Subscription & GMP

Subscription by category

Total subscribed179.07×

Missing multiples are calculated from bids and offered shares when available.

QIB106.72×
NIB369.94×
RETAIL138.57×

GMP history

017.53512 Mar: ₹3520 Nov: ₹35
12 Mar₹3520 Nov

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs6.79724.41
RETAIL11.881,646.4
NIB5.091,884.46

Financial performance

Company financials

In Lakhs · Reported periods may include interim results.

Revenue & profitIn Lakhs
05,00010,00015,000Mar-22 · Revenue: 9,266.63Mar-22 · Profit after tax: 312.86Mar-22Mar-23 · Revenue: 11,569.65Mar-23 · Profit after tax: 515.29Mar-23Sep-23 · Revenue: 6,948.43Sep-23 · Profit after tax: 539.38Sep-23
RevenueProfit after tax

Key performance indicators

Metric202320222021
EPS4.292.622.52
ROE35.1329.8340.73
ROCE37.2930.0836.52
RONW29.8825.9633.84
PRE IPO(PE)18.400
POST IPO(PE)5.500

Values and labels as reported in the issue data.

Company information

Company profile

Zenith Drugs Limited, founded in 2000, is a pharmaceutical company that manufactures and trades affordable, high-quality medicines, including various generic products. The company operates under WHO-GMP guidelines and holds an ISO 9001:2015 certification, reflecting its focus on quality. It offers a wide product range such as ORS powder, liquid orals, ointments, liquid externals, and capsules, with over 600 products approved by the Food & Drugs Administration and 325 currently in production. Zenith Drugs is expanding by setting up a new manufacturing facility in Muradpura, Depalpur, Indore, and it also exports its products to multiple regions including Central America, Africa, Southeast Asia, and South Asia. The company provides third-party manufacturing services to well-known pharmaceutical brands like Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, and as of March 31, 2023, it employs 89 people, including both payroll and contract staff.

Strengths

  • Experienced Leadership: The company is guided by seasoned promoters and a skilled management team, ensuring strong leadership and strategic growth.
  • Cost Efficiency: A focus on cost-effective operations helps maximize resource use, boosting profitability and competitiveness.
  • Innovation & Development: Strong formulation and development capabilities allow the company to innovate and adapt to market trends, setting it apart from competitors.
  • Regulatory Compliance: Strict adherence to regulations ensures smooth operations, reduces risks, and strengthens the company’s reputation.
  • Global Presence: A broad international market reach helps diversify revenue streams and reduces reliance on any single region.

Risk factors

  • Restrictive Financing Conditions: The company must get lender approval for financial decisions like borrowing or restructuring, which may limit flexibility in operations.
  • Raw Material & Supplier Dependency: Relying on key suppliers without long-term contracts poses a risk—any shortages or price hikes could impact production and profitability.
  • Manufacturing & Quality Risks: Any issues in production or quality control could disrupt operations, harm the company’s reputation, and lead to potential legal challenges.
  • Rising Competition: Failure to keep up with increasing competition could result in lower market share and reduced profitability.
  • Customer Payment Delays: Late or missed payments from customers could strain cash flow, affecting daily operations and financial stability.

Promoters

Mr. Sandeep Bhardwaj

Mr. Bhupesh Soni

Mr. Ajay Singh Dassundi

Registrar & documents

Lead manager

Gretex Corporate Services Limited

Registered office

K. No. 72 / 5, Village Muradpura NA Depalpur, Indore-453001

+91 8435501867

[email protected]Company website ↗

Frequently Asked Questions

What is Zenith Drugs IPO GMP today?

As of today, Zenith Drugs IPO Grey Market Premium (GMP) is reported at +₹35 per share. Based on the upper price band of ₹79, the estimated listing price is ₹114 (+44.3% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Zenith Drugs IPO?

The minimum bid lot size for Zenith Drugs IPO is 1,600 shares. At the cut-off price of ₹79 per share, retail investors need a minimum application amount of ₹1,26,400 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).

When will Zenith Drugs IPO allotment status be announced?

The allotment status for Zenith Drugs IPO is scheduled to be finalized on 23 Feb 2024. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Bigshare Services Private Limited's official portal or via BSE/NSE allotment portals.

How can I check Zenith Drugs IPO allotment status online by PAN?

To check Zenith Drugs IPO allotment status: 1) Visit the registrar portal (Bigshare Services Private Limited) or the BSE IPO allotment page. 2) Select 'Zenith Drugs Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.
Zenith Drugs IPO GMP Today, Subscription Status & Allotment Date | IPO Premiums